Prevalence and intensity of basic symptoms among cannabis users: an observational study

REFERENCES

• Wells B, Stacey B. A further comparison of cannabis (marijuana) users and non-users. Br J Addict Alcohol Other Drugs 1976; 71(2):161–165.
   PubMedGoogle Scholar
• Stein JA, Newcomb MD, Bentler PM. Personality and drug use: Reciprocal effects across four years. Pers Individ Dif 1987; 8:419–430.
   Web of Science ®Google Scholar
• Sieber MF, Alcohol AJ. Tobacco and cannabis: 12-year longitudinal associations with antecedent social context and personality. Drug Alcohol Depend 1990; 25(3):281–292.
   PubMed Web of Science ®Google Scholar
• Newcomb MD, Scheier LM, Bentler PM. Effects of adolescent drug use on adult mental health. A prospective study of a community sample. Exp Clin Psychopharmacol 1993; 1:214–215.
   Web of Science ®Google Scholar
• Guy SM, Smith GM, Bentler PM. Consequences of adolescent drug use and personality factors on adult drug use. J Drug Educ 1994; 24:109–132.
   PubMed Web of Science ®Google Scholar
• Williams JH, Wellman NA, Rawlins JN. Cannabis use correlates with schizotypy in healthy people. Addiction 1996; 91(6):869–877.
   PubMed Web of Science ®Google Scholar
• Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, Lewis S. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 2008; 41(6):371–378.
   Google Scholar
• Keeler MH, Ewing JA, Rouse BA. Hallucinogenic effects of marijuana as currently used. Am J Psychiatry 1971; 128(2):213–216.
   PubMed Web of Science ®Google Scholar
• Tart CT. Marijuana intoxication common experiences. Nature 1970; 226(5247):701–704.
   Google Scholar
• Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001; 31(4):659–668.
   PubMed Web of Science ®Google Scholar
• van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002; 156(4):319–327.
   PubMed Web of Science ®Google Scholar
• McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15(3):277–281.
   PubMed Web of Science ®Google Scholar
• Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2(8574):1483–1486.
   PubMed Web of Science ®Google Scholar
• Allebeck P, Adamsson C, Engström A, Rydberg U. Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 1993; 88(1):21–24.
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. Br Med J 2002; 325(7374):1212–1213.
   PubMed Web of Science ®Google Scholar
• Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33(1):15–21.
   PubMed Web of Science ®Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51(4):273–279.
   PubMed Web of Science ®Google Scholar
• Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry 1995; 29(1):69–74.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Thies M, Münte TF, Emrich HM. Effects of synthetic delta-9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl) 1999; 142(3):230–235.
   PubMed Web of Science ®Google Scholar
• Semple DM, Ramsden F, McIntosh AM. Reduced binocular depth inversion in regular cannabis users. Pharmacol Biochem Behav 2003; 75(4):789–793.
   PubMed Web of Science ®Google Scholar
• Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7(5):515–518.
   PubMed Web of Science ®Google Scholar
• Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56(4):803–807.
   PubMed Web of Science ®Google Scholar
• Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008; 65(7):772–784.
   PubMed Web of Science ®Google Scholar
• Kwapil TR. A longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. J Abnorm Psychol 1996; 105(1):114–123.
   PubMed Web of Science ®Google Scholar
• Mass R, Bardong C, Kindl K, Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology 2001; 34(4):209–214.
   PubMed Web of Science ®Google Scholar
• Dumas P, Saoud M, Bouafia S, Gutknecht C, Ecochard R, Daléry J, Rochet T, d'Amato T. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res 2002; 109(1):27–35.
   PubMed Web of Science ®Google Scholar
• Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996; 42(3):201–207.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychol Med 2003; 33(1):23–32.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr Res 2003; 59(1):77–84.
   PubMed Web of Science ®Google Scholar
• Huber C. Die coenästhetische Schizophrenie. Fortschr Neurol Psychiatr 1957; 25:491–520.
   Google Scholar
• Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. Compr Psychiatry 1999; 40(5):363–371.
   PubMed Web of Science ®Google Scholar
• Klosterkötter J, Schultze-Lutter F, Gross G, Huber G, Steinmeyer EM. Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: An 8-year average follow-up prospective study. Acta Psychiatr Scand 1997; 95(5):396–404.
   PubMed Web of Science ®Google Scholar
• Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58(2):158–164.
   PubMed Web of Science ®Google Scholar
• Chapman J. The early symptoms of schizophrenia. Br J Psychiatry 1966; 112(484):225–251.
   PubMed Web of Science ®Google Scholar
• Peralta V, Cuesta MJ. Subjective experiences in schizophrenia: A critical review. Compr Psychiatry 1994; 35(3):198–204.
   PubMed Web of Science ®Google Scholar
• Süllwold L. Symptome schizophrener Erkrankungen. Uncharakteristische Basisstörungen. Berlin, Germany: Springer, 1977.
   Google Scholar
• Süllwold L. Frankfurter Beschwerde-Frageboden (FBF). In Schizophrene Basisstorungen. Süllwold L, Huber G, eds. Berlin, Germany: Springer, 1986; 1–36.
   Google Scholar
• Duke PJ, Pantelis C, Barnes TRE. South Westminster Schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994; 164:630–636.
   PubMed Web of Science ®Google Scholar
• Duke PJ, Pantelis C, McPhillips MA, Barnes TRE. Comorbid substance misuse among people with schizophrenia in the community: An epidemiological study in central London. Br J Psychiatry 2001; 179:501–513.
   Web of Science ®Google Scholar
• Stanghellini G, Ricca V, Quercioli L, Cabras PL. FBF Questionario dei Sintomi-Base. Firenze: Organizzazioni Speciali, 1991.
   Google Scholar
• Williams RM, Alagaratnam W, Hemsley DR. Relationship between subjective self-report of cognitive dysfunction and objective information-processing performance in a group of hospitalized schizophrenic patients. Eur Arch Psychiatry Neurol Sci 1984; 234:48–53.
   PubMedGoogle Scholar
• Mass R. Characteristic subjective experiences of schizophrenia. Schizophr Bull 2000; 26(4):921–931.
   PubMed Web of Science ®Google Scholar
• Moritz S, Lambert M, Andresen B, Böthern A, Naber D, Krausz M. Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients. Compr Psychiatry 2001; 42(3):213–216.
   PubMed Web of Science ®Google Scholar
• Vallina Fernández O, Lemos Giráldez S, García Sáiz A, Otero García A, Alonso Sánchez M, Gutiérrez Pérez A. Integrated psychological treatment for schizophrenic patients. Psychol Spain 1999; 3:25–35.
   Google Scholar
• Moritz S, Krausz M, Gottwalz E, Andresen B. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms. Compr Psychiatry 2000; 41(4):284–288.
   PubMed Web of Science ®Google Scholar
• Cohen P, Chen H, Crawford TN, Brook JS, Gordon K. Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug Alcohol Depend 2007; 88(Suppl. 1):S71–S84.
   PubMed Web of Science ®Google Scholar
• Yon V, Loas G, Brien D. Subjective experiences and the psychopathological dimensions in schizophrenia. Psychiatry Res 2005; 137(1–2):93–102.
   PubMed Web of Science ®Google Scholar
• Mass R, Haasen C, Krausz M. Dimensional structure and diagnostic specificity of the Frankfurt Complaint Questionnaire. Eur Psychiatry 1997; 12:117–123.
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29(11):2108–2114.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr Res 2007; 94(1–3):29–36.
   PubMed Web of Science ®Google Scholar
• EMCDDA. 2009 – European Monitoring Centre for Drugs and Drug Addiction. Available at http://www.emcdda.europa.eu/publications/country-overviews/it. Last accessed on September 15, 2009.
   Google Scholar
• Small E, Beckstead HD, Chan A. The evolution of cannabinoid phenotypes in cannabis. Econ Bot 1975; 29:219–232.
   Web of Science ®Google Scholar
• Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3):271–280.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192(4):306–307.
   PubMed Web of Science ®Google Scholar